The data underlying the results presented in the study are available from NCBI at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141208>.

Introduction {#sec001}
============

miRNAs are an important class of small RNAs discovered in *C*. *elegans* in 1993. They have been detected in plants, animals and some viruses. Inside cells, miRNAs are mostly down regulators of gene expression, interfering with the process of mRNA translation into proteins \[[@pone.0231394.ref001]\]\[[@pone.0231394.ref002]\]\[[@pone.0231394.ref003]\]. In humans, approximately 2600 mature miRNAs have been reported in the curated miRNAs registry, the miRBase \[[@pone.0231394.ref004]\]. Many of the human miRNAs have only recently been identified using miRNAseq. Consequently, many of these miRNA's have not yet had experimentally supported biological functions attributed to them \[[@pone.0231394.ref005]\]. These small molecules have also been found circulating in human plasma, serum and in other body fluids including saliva, milk, urine, and semen. In plasma, miRNAs associate with Argonaut proteins and can also be detected inside extracellular vesicles or exosomes \[[@pone.0231394.ref006]\]\[[@pone.0231394.ref007]\].

In plasma, exosomes are part of extracellular vesicles (EVs) which include particles of diverse sizes and origins that are not fully characterized. There is no standard definition for what exosomes are. In practical terms, these are mixed populations of membranous nanosized particles about 50--130 nm in diameter \[[@pone.0231394.ref008]\]\[[@pone.0231394.ref009]\]\[[@pone.0231394.ref010]\]. They contain biochemically diverse molecules including miRNAs, long non coding RNA, DNA and proteins from the cell from which they originate and are actively released. Nonetheless, EVs are able to change the transcriptional context of distant target cells by fusing their membrane to that of the target cell and releasing their cargo within the cell \[[@pone.0231394.ref011]\]. EVs and Argonaut proteins protect miRNAs from RNAse present in plasma, rendering miRNAs very stable in blood \[[@pone.0231394.ref012]\]\[[@pone.0231394.ref013]\]. The functional convergence of EVs and miRNAs constitutes a long distance cell communication system that has been recognized as such during the last decade \[[@pone.0231394.ref014]\]. Currently, there is active ongoing research into the biochemical and functional characterization of EV contents and their membrane proteins. EVs have also been implicated in the tissue specific tropism of metastatic processes in breast cancer \[[@pone.0231394.ref010]\]\[[@pone.0231394.ref015]\]\[[@pone.0231394.ref016]\]. Part of the interest in EVs stems from their potential as a rich source of biomarkers using minimally invasive techniques. Although there is no direct path for developing clinically useful biomarkers, some recently reported attributes of miRNA profiles in plasma or serum make them good candidates for use as biomarkers. Examples of these include profiles in cancer patients that can differentiate different types of tumors, or tumor profile correlations with tumor progression \[[@pone.0231394.ref017]\]\[[@pone.0231394.ref018]\]\[[@pone.0231394.ref012]\].

Microarrays for analyzing the miRNome {#sec002}
-------------------------------------

High-throughput expression microarray technology can now scan complete miRNnomes or transcriptomes in a single hybridization experiment. The original technology used a double channel platform and yielded relative measurements. However, more mature technology with one-channel platforms include calibrators, which yield absolute measurements. These calibrators allowed the development of robust methods for detection calls \[[@pone.0231394.ref019]\], which are basically ignored by most analysis. Broad maps of what is detected and what is not can be generated with the detection score using clustering tools thus facilitating data interpretation \[[@pone.0231394.ref020]\]. This approach allows answering relevant questions, such as ´how many´ and ´which´ miRNAs can be detected in plasma or EVs? Similarly, one can now posit: ´Are detectable miRNAs shared by all samples, phenotypes or experimental conditions? ´

Here, using the detection score that microarrays analysis provide, we report results obtained with panoramic and simplified mirnomic graphs from plasma and corresponding EVs, allowing us to determine miRNA contents in these two blood compartments. Using unsupervised hierarchical clustering with Venn diagrams \[[@pone.0231394.ref021]\], and contrasting them with differential analysis, we discovered miRNA clusters shared by all the children with retinoblastoma \[Rb\] cases, clusters shared by all healthy controls, one small cluster shared by all samples and some miRNAs related to sex. We further discuss the relationship of these miRNAs with the corresponding tumor miRNA profiles that we had previously reported, and propose that those miRNAs consistently detected in all samples can serve as novel circulating normalizers.

Methods {#sec003}
=======

This research was approved by Comisión Nacional de Investigación Científica and Comisión de Bioética IMSS. Also by the Comité Local de Investigación y Bioética, Hospital de Pediatría Silvestre Frenk Freund, CMN SXXI, IMSS.

Patients and samples {#sec004}
--------------------

We examined samples from 12 children with retinoblastoma and 12 children without retinoblastoma and all children were of Hispanic ethnicity. Inclusion criteria: children newly diagnosed with retinoblastoma at an age of less than or equal to 6 years since most affected patients are in this age group. Without a known genetic syndrome or prior diagnosis of cancer, who were diagnosed or were receiving treatment at the two participating treatment centers, and did not have a preexisting or known family history of retinoblastoma. One child later found to have familial retinoblastoma was included in the study. Controls were healthy children with the same inclusion criteria as cases, who were recruited as friend controls as previously described \[[@pone.0231394.ref022]\]. Exclusion criteria: age greater than 6 years, known diagnosis of a genetic syndrome or prior diagnosis of cancer.

All samples were collected after obtaining written informed parental consent to participate in a larger IRB approved case-control study. Because of the age of children, assent was not required. The children were patients diagnosed and receiving treatment at Hospital de Pediatría Silvestre Frenk at Centro Médico Nacional Siglo XXI, from Instituto Mexicano del Seguro Social (IMSS), and Hospital Infantil de México Federico Gómez, from Secretaría de Salud in Mexico City during the years 2004 to 2012 as previously described \[[@pone.0231394.ref022]\]\[[@pone.0231394.ref023]\].

Plasma samples {#sec005}
--------------

All blood samples were obtained prior to the child's receiving any chemotherapy or radiation, and were drawn into Becton Dickinson CPT tubes (Becton Dickinson, Franklin Lakes, NJ USA) with citrate as anticoagulant and stored at 4°C until separation by centrifugation. Samples were fractionated within 24 hours of collection. Plasma aliquots of 1 ml were stored at -80° C until processed for isolation of EVs and RNA extraction.

Extracellular vesicles (EVs) {#sec006}
----------------------------

EVs were isolated from 0.5 ml of each plasma sample with an initial centrifugation at 2000 x g to remove any insoluble material. Supernatant was then diluted with PBS 2:1 and filtered with a syringe driven filter unit 0.22-micron pore, (Millex, Millipore SLGV033RS). Each resulting sample was mixed with 5:1 Exosome Isolation Reagent (Invitrogen 4478359), incubated on ice for 10 minutes and then centrifuged at 10,000 x g for 30 minutes. Precipitated material was resuspended in 100 microliters (μl) PBS and stored at -20°C until processed for RNA isolation. We used electron microscopy to visualize EVs \[[@pone.0231394.ref024]\].

RNA isolation and labeling for microarrays {#sec007}
------------------------------------------

Total RNA was isolated from 0.5 ml of each plasma sample, and from 100 μl of purified EVs using TRIzol reagent (Invitrogen 15596026), solubilized in nuclease free water and quantified using a Nanodrop. RNA 150 ng was poly-A tailed and biotin incorporated into tails with Flash Tag biotin for miRNA microarrays (Affymetrix 901911), including an Enzyme Linked Oligosorbent Assay (ELOSA) to confirm biotin labeling according to manufacturer instructions and as previously described \[[@pone.0231394.ref020]\].

miRNA microarrays {#sec008}
-----------------

Hybridization mix was added to labeled samples containing 2X hybridization mix, 27% formamide, DMSO and 20X hybridization control probes in nuclease free water. Each sample was introduced into a GeneChip miRNA 4 array (Affymetrix 902411), hybridized at 48°C for 18 h. Each sample was washed in the GenChip Fluidics Station 450 following FS450-0002 protocol, and array fluorescence was measured by the Gene Chip Scanner 3000 7 G

Data analysis {#sec009}
-------------

Demographic characteristics of the sample of 12 children with Rb and the 12 healthy controls were compared with Mann Whitney and Chi Square tests using SPSS v26. Raw data from .CEL files with fluorescence signals were preprocessed in Affymetrix Expression Console software (v 1.4.1.46; Affymetrix UK Ltd). Preprocessing included normalization, quality control and detection call. We used Robust Multichip Analysis (RMA) to adjust the signal to noise ratio and to generate CHP files for further analysis. For each probeset or miRNA in the array we obtained two types of data from .CHP files: 1) detection score, categorizing each miRNA as 'present' or 'absent' and 2) detection levels log2 intensity signal data. Algorithms used for detection call metrics were developed and published by the supplier using the Latin Square experimental design; on which artificial transcripts at known concentrations were spiked in a complex background \[[@pone.0231394.ref019]\]. Analysis from this design generates a detection score with an associated *p* value that reflects the confidence of the detected ('present') or not detected ('absent') score, and is very useful when the detection level of a miRNA is close to the local background.

Bioinformatic analysis {#sec010}
----------------------

Detection scores were analyzed and grouped with unsupervised hierarchical clustering (HC) in Multi Experiment Viewer (MEV) from TM4 Microarray Software Suite \[[@pone.0231394.ref025]\]. Differential analysis was performed in R (R core team, 2019) with Bioconductor software package Limma \[[@pone.0231394.ref026]\] incorporating correction for multiple testing. miRNAs with p-values \< 0.05 were grouped by hierarchical clustering and plotted with the R gplots \[[@pone.0231394.ref027]\]. To search for mRNA targets and signaling pathways involved with specific miRNAs we used DIANA-Tools-microT-CDS, miRPathv3, Target-Scan and Tarbase v.7 (at <http://diana.imis.athena-innovation.gr/Diana-Tools/index.php?r_tarbase/index>) \[[@pone.0231394.ref028]\].

Results {#sec011}
=======

Demographic and clinical characteristics of the participants are shown in **[Table 1](#pone.0231394.t001){ref-type="table"}**. Cases and controls were comparable in their distribution of age at time of sample collection as well as in their sex distribution.

10.1371/journal.pone.0231394.t001

###### Select demographic characteristics of the Rb patients and healthy controls whose samples were analyzed.

![](pone.0231394.t001){#pone.0231394.t001g}

  Rb                  Age              Sex   Laterality[\^](#t001fn001){ref-type="table-fn"}   Healthy   Age              Sex
  ------------------- ---------------- ----- ------------------------------------------------- --------- ---------------- -----
  P1                  26               F     B                                                 C1        9                F
  P2                  32               M     B                                                 C2        52               M
  P3                  29               M     B                                                 C3        41               M
  P4                  60               M     U                                                 C4        28               F
  P5                  37               F     U                                                 C5        30               F
  P6                  52               F     U                                                 C6        71               M
  P7                  19               M     U                                                 C7        15               M
  P8                  9                M     B                                                 C8        22               M
  P9                  12               M     B                                                 C9        4                M
  P10                 36               M     U                                                 C10       17               F
  P11                 33               M     U                                                 C11       57               F
  P12                 36               F     U                                                 C12       67               M
  Median (min, max)   31.9 (9, 61.9)                                                                     29.3 (9, 71.5)    

\^ B is bilateral; U is unilateral.

Cases and controls did not differ in age (Mann-Whitney test based on ages in months at the time of sample collection) or in distribution of sex (by Chi Square test).

Mirnomic landscape identify common miRNAs in plasma, EVs and primary tumors from Rb patients {#sec012}
--------------------------------------------------------------------------------------------

To test if plasma and EVs from Rb cases share miRNA elements with the primary tumors, we generated the corresponding plasma and EV datasets and compared these with a publicly available mirnomic dataset of the corresponding tumor tissues that we had previously reported (GEO GSE 84747 and Array Express E-MTAB-4977) \[[@pone.0231394.ref020]\]. With unsupervised hierarchical clustering analysis (clustering both samples and miRNAs), we generated a miRNA detection two-color heatmap of these samples shown in **[Fig 1](#pone.0231394.g001){ref-type="fig"}**.

![Mirnomic detection map of 12 primary retinoblastoma, corresponding plasmas and EVs.\
a. Heatmap obtained with hierarchical clustering using the detection score. Blue means detected miRNA, while black means undetected miRNA. The columns represent samples while the rows represent the miRNAs (2578). The purple bar at the top left indicates the cluster of the tumor samples. The fuchsia arrow to the right indicates a cluster of 18 miRNAs shared by all samples. There are 1998 variably detected miRNAs, which are split into three miRNA clusters: one at the top, one in the middle, and one at the bottom. b. Corresponding dendrogram: the purple branches indicate tumor samples, while black branches indicate plasma or EVs.](pone.0231394.g001){#pone.0231394.g001}

This map shows a panoramic mirnomic view of detected and not detected miRNAs in all samples derived from Rb cases. Near the top there is a small cluster of 18 miRNAs shared by all the samples, indicating these miRNAs detected in the primary tumor, are also detected in circulation (i.e., in plasma and in EV) suggesting the existence of a circulating tumor signature. In this detection map, all retinoblastoma tumor tissues group together, while most plasmas group in the center and most EVs group to the right, although their distribution does not segregate completely. This map shows a higher density of detected miRs in tumors as expected, and there appears to be a higher density of miRNAs in EVs than in plasma.

After obtaining these results, we decided to analyze each circulating compartment separately in order to characterize similarities and differences between children with Rb and healthy controls.

Mirnomic landscapes in plasma from Rb cases and healthy controls {#sec013}
----------------------------------------------------------------

We used the detection scores from Rb plasma cases to generate a mirnomic map that is shown in **[Fig 2A](#pone.0231394.g002){ref-type="fig"}**.

![Analysis from miRNA clusters in plasma shared by all Rb cases and by all healthy controls.\
a. Hierarchical clustering of miRNome from Rb cases, showing in green those detected, and in black, those miRNAs not detected. b. Hierarchical clustering of miRNome from healthy controls showing in red those miRNA detected, and in black those not detected. c. Venn diagrams of the miRNAs shared by all Rb cases and by all healthy control showing a group of 9 miRNAs shared by all children and a 19 miRNA group present exclusively in plasma from children with Rb. d. Venn diagrams demonstrating that 14 of the 19 miRNAs exclusive for Rb cases are also present in the 142 miRNA core reported from the corresponding primary tumors \[[@pone.0231394.ref020]\].](pone.0231394.g002){#pone.0231394.g002}

miRNAs detected in plasma from Rb patients are shown in green and those miRNAs not detected are in black. This map shows a mirnomic detection view composed of three types of clusters. First, at the bottom, one cluster with 1435 miRNAs uniformly not detected in all the samples; second, an upper cluster with 1115 miRNAs variably detected across samples; and third, within the upper cluster there is a remarkably small nested cluster of 28 miRNAs shared by all plasma samples from Rb patients. In order to compare this plasma map from Rb cases with those from healthy controls, we generated the same type of mirnomic map with plasma from healthy controls shown in **[Fig 2B](#pone.0231394.g002){ref-type="fig"}**. One pair of plasma/EVs from healthy controls yielded unreliable quality controls and was excluded from further analysis. The mirnomic map in plasma from the remaining 11 controls overall shows a structural similarity with that of the Rb cases, but the number of miRNAs in each cluster differs. There is a large cluster of 1372 miRNAs that are uniformly not detected, a group of 1193 variably detected miRNAs and a smaller nested cluster that are shared by all plasma samples of the healthy controls which is composed of only 13 miRs. The list of miRs contained in each of these clusters can be found in **[S1](#pone.0231394.s001){ref-type="supplementary-material"} and [S2](#pone.0231394.s002){ref-type="supplementary-material"} Lists**.

Comparison of exclusive miRNAs between Rb cases and healthy controls, reveals an Rb signature of 19 miRNAs {#sec014}
----------------------------------------------------------------------------------------------------------

We then focused on the small clusters of 28 miRs shared only among all Rb cases and 13 miRs shared only among all healthy controls. We used Venn diagrams in order to test and discriminate if there are corresponding relationships between these sets. As shown in **[Fig 2C](#pone.0231394.g002){ref-type="fig"}**, there is a subset of 19 miRNAs exclusive to Rb cases, an intersected subset of 9 miRNAs shared by both cases and controls, and a subset of 4 miRs present exclusively in healthy controls. The corresponding list of these miRNAs including the 19 exclusive miRNAs in plasma from Rb cases is found in **[S3 Lists](#pone.0231394.s003){ref-type="supplementary-material"}**. We then explored the corresponding relationships of the 19 miRNAs found exclusively in plasma from Rb cases with the central core of 142 miRNAs previously reported in the primary tumors \[[@pone.0231394.ref020]\]. Results are shown in **[Fig 2D](#pone.0231394.g002){ref-type="fig"}**. There is an intersection between 14 out of 19 miRNAs detected in plasma from the Rb cases that are also detected in retinoblastoma tumor tissue, indicating that 5 miRNAs in circulation are not present in the tumor.

Mirnomic landscapes in EVs from Rb cases and healthy controls {#sec015}
-------------------------------------------------------------

To explore the miRNome in EVs from Rb cases and healthy controls, we generated the same mirnomic detection maps with RNA isolated from EVs. For one Rb case and one healthy control, RNA from the EVs was insufficient for further analysis. In **[Fig 3A and 3B](#pone.0231394.g003){ref-type="fig"}** the detection mirnomic maps show also a broad similarity to the maps generated from plasma miRNomes, and again the number of miRNAs in each cluster is different.

![Analysis from miRNA clusters in EV shared by all Rb cases and by all healthy controls.\
a. Hierarchical clustering of miRNome from EVs/Rb cases showing in yellow those detected, and in black, those not detected. b. Hierarchical clustering of miRNome from EVs controls showing in turquoise blue those detected, and in black, those not detected. c.Comparison using Venn diagrams of miRNAs shared in EVs from all cases with the miRNAs shared in EVs from all controls yields a 13 miRNA group present only in Rb cases. d.From this 13 miRNA group shared only among Rb cases, only 8 are also detected in the 142 miRNA core of the primary tumor.](pone.0231394.g003){#pone.0231394.g003}

Each detection map is composed of a large cluster of non-detected miRNAs, a group of variably detected miRNAs and nested within, small miRNA clusters: a cluster of 36 miRNAs shared in EVs from all Rb cases and a cluster of 30 miRNAs shared in EVs from all controls. The list of miRNAs in these clusters can also be found in **[S4 Lists](#pone.0231394.s004){ref-type="supplementary-material"}**. An analysis of correspondence between EVs from cases and controls performed with Venn diagrams in **[Fig 3C](#pone.0231394.g003){ref-type="fig"}** shows a subset of 13 miRs exclusively detected in EVs from Rb cases, an overlapping subset of 23 miRs shared by both cases and controls, and a subset of 7 miRNAs detected exclusively in EVs from healthy controls (**[S5 List](#pone.0231394.s005){ref-type="supplementary-material"})**. **[Table 2](#pone.0231394.t002){ref-type="table"}** shows a summary of all these clusters and the number of miRNAs belonging to each one.

10.1371/journal.pone.0231394.t002

###### Number of miRNAs in clusters found in plasma and EVs miRNome from Rb cases and healthy controls.

![](pone.0231394.t002){#pone.0231394.t002g}

  miRNome ID               Shared not-detected miRNAs   Variably detected miRNAs   Shared miRNAs
  ------------------------ ---------------------------- -------------------------- ---------------
  Rb Cases Plasma          **1435**                     1115                       28
  Rb Cases EVs             1409                         1137                       **32**
  Retinoblastoma tissues   995                          1441                       142
  Healthy Controls         1317                         **1248**                   13
  Healthy Controls EVs     1378                         1170                       30

In bold type are the highest number of miRNAs for each class of clusters in plasma and EVs: not-detected in all, variably detected in all, shared detected in all.

To explore how many of the 13 miRNAs that were exclusive to EV from cases were also detected in the primary tumor, we also performed a correspondence test against the central 142 miRNA core using Venn diagrams, and found that 8 out of these 13 miRNAs were also detected in the primary tumor as shown in **[Fig 3D](#pone.0231394.g003){ref-type="fig"}**.

Differential analysis performed poorly between Rb cases and healthy controls {#sec016}
----------------------------------------------------------------------------

With two putative Rb case signatures, one with 19 miRs in plasma and one with 13 miRs in EVs, we subsequently asked if differential analysis using the detection levels would also be able to identify these signatures. Using Limma \[[@pone.0231394.ref026]\] in R from Bioconductor and setting a *p* value \< 0.05, we performed differential analysis in miRNAs between Rb and healthy controls first among plasma samples and then among EVs. In the differential analysis, we found 158 differentially expressed miRNAs in plasma and 142 differentially expressed miRNAs in EVs. However, adjusted *p values* indicate that differences were not significant for any of them. Only 5 miRNAs from the signatures were overexpressed in Rb: 3 of these were detected in plasma and 2 in EVs. The highest differentially expressed miRNAs are shown in Tables [3](#pone.0231394.t003){ref-type="table"} and [4](#pone.0231394.t004){ref-type="table"}.

10.1371/journal.pone.0231394.t003

###### The most differentially expressed miRNAs in Rb cases.

![](pone.0231394.t003){#pone.0231394.t003g}

  miRNA             logFC   AveExpr   t       *p value*   adj. *p val*
  ----------------- ------- --------- ------- ----------- --------------
  hsa-miR-3613-3p   2.852   7.792     2.675   0.013       0.808
  hsa-miR-4529-3p   2.803   5.069     2.356   0.027       0.833
  hsa-miR-4668-5p   2.087   7.569     2.159   0.041       0.833
  hsa-miR-4508      1.345   3.287     3.397   0.002       0.667

10.1371/journal.pone.0231394.t004

###### The most differentially expressed miRNAs in EVs Rb cases.

![](pone.0231394.t004){#pone.0231394.t004g}

  EVs Rb cases                                      
  ----------------- ------- ------- ------- ------- -------
  hsa-miR-4529-3p   2.656   4.323   3.074   0.006   0.784
  hsa-miR-6800-3p   0.937   2.958   2.189   0.04    0.784
  hsa-miR-3921      0.797   2.919   2.566   0.018   0.784

The cells shaded in yellow correspond to those miRNAs that were also identified by our alternate method in the cluster of shared miRNAs, in [Table 2](#pone.0231394.t002){ref-type="table"} our proposed signature.

The corresponding heatmap does not show color differences among cases and controls except for the 158 and 142 differentially expressed miRNAs, which are shown in **[Fig 4](#pone.0231394.g004){ref-type="fig"}.** Even though differential analysis identified miRNAs with p-values \<0.05, the adjusted p-values did not show any statistically significant differences between Rb cases and controls for any miRNA not in plasma not in EVs.

![Differential expression analysis using detection levels.\
a. A heatmap showing the 158 most differentially expressed miRNAs in plasma. miRNAs with higher detection levels are represented in red, while miRNAs with lower detection levels are in blue, and those with no significant difference are shown in white. The blue and yellow bar on top of the figure indicates samples from Rb cases and samples from healthy controls respectively. b. Volcano plots illustrate fold change (log base 2) compared with *p* value (−log base 10). The three labeled miRNAs were those that were also identified in the cluster of miRNAs shared in the plasma from all Rb cases. c. A Heatmap showing the top 142 differentially expressed miRNAs in EVs. d.Indicated miRNAs also identified in the cluster of shared miRNAs in EVs from all Rb cases.](pone.0231394.g004){#pone.0231394.g004}

Plasma signature of 19 miRNAs discriminates correctly Rb cases from healthy controls {#sec017}
------------------------------------------------------------------------------------

Since 19 miRNAs as a group or signature are detected in plasma from all Rb cases, and 13 miRNAs as a signature are detected in EVs from Rb cases, we plotted the profile detection scores against controls to test how well the signatures were able to distinguish both groups. The discriminating ability of the 19 miRNAs plasma profile is illustrated in **[Fig 5A](#pone.0231394.g005){ref-type="fig"}.** Importantly, not a single control had the 19 miRNA signature.

![Detection score maps of Rb signatures against healthy controls.\
a. The 19 miRNAs signature consistently detected in plasma from all Rb cases distinguish correctly all controls. The 13 miRNA signature consistently detected in EVs from Rb cases cannot distinguish correctly all controls, red asterisks indicate those healthy controls with EVs Rb profiles. b. Detection levels of the 19 and 13 Rb signatures found in plasma and EVs respectively are above the average. c. Summary of shared and exclusive clusters found among Rb cases and healthy controls. The dark yellow box highlights the cluster able to discriminate Rb cases from all healthy controls.](pone.0231394.g005){#pone.0231394.g005}

In contrast, the 13 miRNA profile from EVs cannot distinguish both classes, as two healthy controls display the 13 miRNA signature corresponding to Rb patients. This indicates that the more robust circulating Rb case signature is in the plasma compartment not in EVs.

In order to evaluate the abundance of the 19 miRNA circulating signature, we shifted to analysis of detection levels. We plotted in histograms the average signal for each miRNA across the plasma dataset obtained from Rb cases. **[Fig 5B](#pone.0231394.g005){ref-type="fig"}** shows that all signals are well above the general average. In an attempt to compact the 19 miRNA signature found in Rb plasmas, we tested the correspondence between the 19 and the 13 miRNA signature found in Rb plasma and EVs using Venn diagrams. Even though we found an overlapping set of 7 miRNAs present in both compartments, the discriminating power of this 7miRNA 'signature' performed worse than the parental 13 signature found in EVs, and was not able to distinguish 5 individuals as controls. A summary of shared clusters and intersected results with Venn diagrams described here are illustrated in **[Fig 5C](#pone.0231394.g005){ref-type="fig"}**.

The detection mirnomic scores reveal the size of the circulating miRNome {#sec018}
------------------------------------------------------------------------

An important application of the detection score is the possibility to describe and summarize the number of detected miRNAs per sample, per group (cases or controls) and per class (all the children in this study). The results of this exploration are presented in **[Table 5](#pone.0231394.t005){ref-type="table"}**.

10.1371/journal.pone.0231394.t005

###### Plasma and EVs miRNome size described using detected miRNAs in Rb cases and healthy controls.

![](pone.0231394.t005){#pone.0231394.t005g}

  ---------------------------------------------------------------------------------------
                                                          Mean        Minimum   Maximum
  ------------------------------------------------------- ----------- --------- ---------
  miRNAs in plasma[\*](#t005fn001){ref-type="table-fn"}   537         398       690

  miRNAs in EVs[\*](#t005fn001){ref-type="table-fn"}      **625.2**   452       846

  miRNAs in plasma from Rb cases                          534.7       454       690

  miRNAs in plasma from healthy controls                  **540**     398       634

  miRNAs in EVs from\                                     **656.2**   506       846
  Rb cases                                                                      

  miRNAs in EVs from\                                     596.9       452       756
  healthy controls                                                              
  ---------------------------------------------------------------------------------------

\*Cases and controls combined

Bolded text signals the highest number of miRNAs analyzed from each compartment.

The number of miRNAs detected in plasma is approximately the same for cases and controls, with an average of 534.7 miRNAs for plasma cases and 540 for plasma controls. In contrast, the average number of miRNAs detected in EVs from cases, 656.2, is higher than the average number of miRNAs detected in EVs from controls, 596. Thus, we found 60 miRNAs more in EVs from cases than in controls. The average size of the circulating miRNome in plasma for these children is 537 miRNAs, while the miRNome size in EVs is an average of 625 miRNAs, with an overall difference of 88 more miRNAs in EVs than in plasma.

Common miRNAs shared by Rb cases and healthy controls may be useful as references or normalizers {#sec019}
------------------------------------------------------------------------------------------------

Considering that the methodological approach presented here, can identify distinctive and unbiased miRNAs among groups or classes, with the use of the detection score, we explored whether detectable miRNAs shared across all the samples could identify potential endogenous normalizers. To do this we generated a dataset with detection scores from every sample (plasma and EVs) in this study and performed a hierarchical clustering analysis. As shown in **[Fig 6A](#pone.0231394.g006){ref-type="fig"}**, there is indeed a small group of 9 miRNAs that is consistently detectable in every sample. This constitutes a relevant intergroup stability feature.

![Detected miRNAs across all samples.\
a. Hierarchical clustering with all datasets used in this study identified a 9 miRNA cluster detected in all samples. Variance across groups including the primary tumors is shown for the three miRNAs that had lower variance. b. The Detection score in plasma for those miRNAs commonly used as normalizers. c. The Detection score in EVs for the same miRNAs.](pone.0231394.g006){#pone.0231394.g006}

Next, to determine how much variability these miRNAs had across the whole group, we shifted the analysis to the corresponding detection levels and calculated the variance for each of these 9 miRNAs. **[Table 6](#pone.0231394.t006){ref-type="table"}** shows that miRNA-5787, miR-638 and miRNA-6732-5p had the lowest variance within our dataset.

10.1371/journal.pone.0231394.t006

###### Variance analysis and detection level of new potential blood miRNAs normalizers miRNAs detected in all samples.

![](pone.0231394.t006){#pone.0231394.t006g}

  ------------------------------------------------------------------
  miRNAs ID         Variance   Detection level\   Detection level\
                               Average            Median
  ----------------- ---------- ------------------ ------------------
  hsa-miR-5787      0.60       9.71               10.40

  hsa-miR-638       1.19       9.78               9.82

  hsa-miR-6732-5p   2.31       4.24               3.77

  hsa-miR-6803-5p   3.02       6.22               6.56

  hsa-miR-8075      3.25       6.23               6.45

  hsa-miR-877-5p    3.41       9.52               9.57

  hsa-miR-4787-5p   4.34       8.20               8.70

  hsa-miR-4487      4.98       9.97               10.56

  hsa-miR-6750-5p   5.77       8.94               9.43
  ------------------------------------------------------------------

The plotted variance data of these three miRNAs is shown in **[Fig 6A](#pone.0231394.g006){ref-type="fig"}**, and is disaggregated by blood compartment (plasma/EVs) and by group (Rb cases/controls) including data from the primary tumors. This results show considerable inter and intragroup stability. Additionally the high detection levels of these three miRNAs suggest that they are potential endogenous plasma normalizers.

To contrast the detection score and variance analysis of these potential endogenous normalizers with some normalizers currently used in plasma, we plotted detection scores of miR-16, miR-21 (common normalizers used in qRT-PCR) across all samples in **[Fig 6B](#pone.0231394.g006){ref-type="fig"}**. It was interesting to note that miR-16-5p signals were detectable only in 17 of 21 samples, and were mainly present in EVs. In contrast, miR-21 is detected only in a few samples. Consistent with this detection data, we show the variance analysis and detection levels of these two miRNAs at the bottom of **[Table 7](#pone.0231394.t007){ref-type="table"}.** It is important to note that detection levels are rather low.

10.1371/journal.pone.0231394.t007

###### Variance analysis and detection levels of common normalizers in use miRNAs commonly used as qRT-PCR normalizers in blood.

![](pone.0231394.t007){#pone.0231394.t007g}

  ------------------------------------------------------------------
  miRNAs ID         Variance   Detection level\   Detection level\
                               Average            Median
  ----------------- ---------- ------------------ ------------------
  hsa-miR-21-5p     0.67       1.38               1.22

  hsa-miR-21-3p     0.02       1.26               1.26

  hsa-miR-16-5p     15.89      4.24               1.57

  hsa-miR-16-1-3p   0.05       1.23               1.21
  ------------------------------------------------------------------

Mirnomic analysis by sex {#sec020}
------------------------

Further exploration with this analytical approach led us to considering participant's sex and test if the sex of individuals in the whole group could allow us to find associated miRNAs. Results in **[Fig 7](#pone.0231394.g007){ref-type="fig"}** show that all females shared 14 miRNAs while all males shared 13 miRNAs. Venn diagrams show the 9 overlapping miRNAs are those analyzed in the previous section, while 5 miRNAs were detected exclusively in females and 4 miRNAs were detected exclusively in males (**[S6 Lists](#pone.0231394.s006){ref-type="supplementary-material"}**).

![Detected miRNAs shared by girls and boys.\
a. Hierarchical clustering of all females in pink and all males in blue b. Comparison with Venn diagrams of miRNAs shared by all females and miRNAs shared by all males. c. related functional pathways of 3 female specific and 2 male specific miRNAs.](pone.0231394.g007){#pone.0231394.g007}

A further search for miRNA targets as well as pathway analysis of these sex associated miRNAs using miRPathv3, TargetScan and TarBase v7, indicated that some of these miRNA targets and pathways were related to estrogen and thyroid signaling pathways in females and steroid biosynthesis in males among others.

Discussion {#sec021}
==========

As part of an international and multi institutional study to determine risk factors for retinoblastoma \[[@pone.0231394.ref022]\], we created a bio repository of frozen plasma from children with Rb and healthy controls. In a group of those plasma samples, we tested whether miRNA profiles are able to discriminate Rb cases from healthy controls. This work is an extension of a previous effort to define the mirnomic view in primary retinoblastoma tissue \[[@pone.0231394.ref020]\]. We now define the mirnomic view of the corresponding plasmas, further comparing them with healthy controls.

We propose a novel approach for 'signal' treatment that simplifies and enables the discovery of meaningful miRNA data patterns in two blood compartments, total plasma and EVs. In the search for biologically informative and clinically meaningful biomarkers for cancer, it is important to know which information can be found in the different blood compartments. Our finding that miRNA contents in total plasma and EVs are distinct may be particularly informative. One possible explanation may be that the purification of EVs may amplify signals from miRNAs that may not be detectable in miRNAs extracted from whole plasma. Importantly, the 19 miRNA signature that is able to discriminate Rb cases from healthy controls is found only in RNA from total plasma and not in EVs, this is relevant because the method to obtain RNA from plasma is simpler and less expensive than the method to obtain RNA from of EVs.

We opted to use the concept of "detection" levels instead of "expression" levels, because plasma is essentially an extracellular biofluid, EVs are not cells, and 'expression level' refers to an intracellular biological phenomenon.

An important measurement that detection scores can provide is the miRNome size. In fact, size of the circulating miRNome has not previously been reported. Even though the number of samples analyzed is too small to permit examination of statistical significance, the information we report constitutes firm steps towards establishing the biological meaning of these differences.

One of the motivations to do this study is the remarkable stability reported for miRNAs in plasma. In order to assure reproducibility the samples have been collected and processed under standard procedures. Our analytic approach focused first on generating the detection score that simplifies microarray data, and later on examination of expression measurements. In our pilot work, we performed technical replicas, and since both expression and detection data were highly correlated, we opted to prioritize and include more biological replicas in our design instead of additional technical replicas, to increase the possibilities of finding patterns shared by Rb cases. Expression measurements in microarray platforms are very sensitive and detect large amounts of 'noise', we believe that this sensitivity masks underlying data patterns, which are unmasked by using the detection score. This noise reduction in the signals facilitates the recognition of patterns in the data when using unsupervised algorithms.

Using clinical information as guides to find molecular associations, allowed the discovery of regularities in the data and molecular patterns associated to Rb cases, associated to healthy controls, associated to all samples, and associated to male or to females. The use of clinical descriptors in combination with detection score analysis is the key methodology that allowed us to discover, more accurate biological molecular relationships and to better interpret the data.

In the plasma from children with Rb, we discovered a group of 19 miRNAs shared by all Rb cases that are present as a profile or molecular signature in all our Rb cases and not in healthy controls. In this signature, there are 14 miRNAs also detected in the corresponding primary tumor, presumably a circulating tumor signature, and it is interesting that 5 miRNAs in this signature are not detected in the tumor miRNA core. Even though there are more miRNAs in EVs than in plasma, it is remarkable that the most robust pattern able to discriminate cases from controls is not present in EVs and is present in total plasma. At this moment, we can only speculate about why the plasma signature clearly better discriminates Rb cases from healthy controls compared with the EVs signature. One possibility is that detectable miRNAs in plasma might reflect both the circulating tumor message as well as a systemic response to cancer.

Differential analysis found miRNAs that significantly differentiated Rb case from those of controls, though none remained statistically significant after adjustment. This indicates that individual miRNA differences between Rb cases and controls are not very strong. Instead, this suggests that useful and robust miRNA differences will more likely be based on a combination of larger miRNA groups or patterns.

We also discovered a small cluster of 9 miRNAs shared across all the samples, the low variance across the samples supports its potential use as a circulating normalizers. Our results add precision and expand information on miR-16-5p and miR-21 common normalizers for qRT-PCR in plasma, since we show that the blood compartment on which miR-16-5p is detected in most samples are EVs. We also show and contrast average detection levels as well as variability measurements (variance) across the samples under study. The expression levels between these common normalizers and the three most highly expressed newly proposed normalizers (miR-5787, 638 and 6732-5p) show that the later have higher detection levels and justify to continue the experimental exploration for using them as normalizers.

Our approach affords a glimpse into parameters for sensibility and specificity that can be used in the development of useful biomarkers. A limitation is that we were only able to partially validate a few miRNAs with qRT-PCR. One potential explanation for this may be an enzymatic amplification bias suggesting a need for better methods for miRNA detection and quantification.

Conclusions {#sec022}
===========

The possibility to study components of malignant solid tumors in blood, whether DNA, RNA or EVs, in other words, the so-called 'liquid biopsy' is a very active and promising field of research. Despite the great interest in this topic, the field itself is still very young, and there are many unknowns in almost every aspect of this field. This study offers a practical approach for navigating and exploring high throughput mirnomic profile data, using a combination of clinical information and unsupervised computational tools in order to reach integrative and plausible interpretations, thus opening up the possibility of differentiating normal and 'not' normal mirnomic profiles.

Supporting information {#sec023}
======================

###### Mirnomic clusters in Rb plasma.
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Click here for additional data file.
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Reviewer \#1: Castro-Magdonel and colleagues carried out a survey on miRNAs from retinoblastoma children's plasma or extracellular vesicles and compared the miRNAs patterns with healthily age matched children, which provided us an informative resource of the landscape analysis of miRNAs in retinoblastoma children.

However, there are some concerns should be addressed before consideration for publication.

The title of the manuscript is too long. Modifications required.

Line 35: Circulating miRNAs are potential useful biomarkers in medicine.

Why they are only important in medicine? The authors should include all the related fields miRNAs involved.

Line 39: To address these questions,

It seemed that the authors did not mention any questions or issues regarding miRNAs in previous couples' sentences. Clarify them.

Line 67: In plasma have been found both, in soluble form associated to Argonaut proteins, and also inside extracellular vesicles or exosomes (6)(7).

This sentence is hard and difficult to understand. Make it readable.

Line 88 to Line 103:

The authors attempted to make their methodology more convincing, logic, and fit their study very well, but they failed. Recommends revision and rearrangements to make it concise and precise.

Materials and methods

The controls and the Rb patients' age and sex are not matched well. Also, the body weight or BMI, and race should be included if it is not unavailable to the authors.

Further, in microarray experiments, variations of expression measurements can be attributed to many different sources that influence the stability and reproducibility of microarray platforms. How the authors handle this issue? Is normalization applied when process the data?

Results and discussions

There are several studies reported about 1000 to 2000 miRNAs in Rb patients' plasma (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493862/>). Why the authors only detected about 600 miRNAs in plasma?

How the authors validate the miRNA expression profile? Any qRT-PCR validation applied?

The figures' resolution is always low, which are difficult to read.

Reviewer \#2: In this paper, the authors try to answer the questions what the differences are between the healthy person and Rb (diseased) person in terms of their miRNAs in plasma and extracellular vesicles using 12 patients and 12 controls. The size of miRNAs in plasma are 537 and in EV is 626. And they found that 19 miRNAs in plasma are significant between healthy and diseased person. And they also found 9 miRNAs that can be detected in all the samples, suggesting that these 9 miRNAs can be used as internal control. They also found that the gender is also a factor that affects the miRNAs between healthy and diseased person. First, I think the English in this paper needs to be improved. Second, I think using 12 patients and 12 control as samples are too few to get conclusion. Third, the difference between the plasmid and EV in terms of its chemical components should be discussed in the paper. Other than that, I have some comments as below:

1\. Methods/Patients and samples: What are including criteria and what are excluding criteria?

2\. How are the healthy control being selected?

3\. How many times the experiments for Fig 1, 2, and 3 are done? If they are only done once, how do the authors make sure the results are reliable?

4\. In figure 3 and 4, how top is the top ranked miRNAs? Are the top miRNAs showed in Table 3 and Table 4 same as those detected by mirnomic analysis?

5\. In Figure 5 and table 5, the authors summarized the number of detected miRNAs per sample, per group (cases or controls) and per class. How does these numbers compare to other mirnome studies?

6\. Figure 7 indicated that gender may be a factor that cause the miRNA to be different. So Could the authors analyze the difference of miRNA in plasma and EV between diseased person and health person with gender differences? So there will be four groups: 1) health female, 2) health male, 3) diseased female, and 4) diseased male.

7\. The authors found that 19 miRNAs shared exclusively by all Rb cases. Are these 19 miRNAs have any similarities? Which pathways did these 19 miRNAs targeted? How about this result compared with other similar results? Is there any difference? If yes, why?

8\. Why "miR-16-5p signals are detectable in 17 / 21 samples mainly in EVs" but not all the samples in EVs? And why "miR-21 is detected only in a few samples" but not all the samples? Since miR-16 and miR-21 are all normalizers, they should be seen in all the samples?

9\. Line 319: "13 miRNAs as a signature are exclusively detected in EVs from Rb cases." Please delete exclusively because it is not exclusive as 12miRNAs are also seen in healthy controls.

10\. Why "more robust circulating Rb case signature is in the plasma compartment not in EVs"? Could the authors give an explanation?

11\. Line 302-303: "the differences are found not too strong" is too subjective. Please revise this sentence, e.g., adding a reference.

12\. Table 1: Did the authors do the statistical analysis on the patient gender between the health and diseased group?

13\. EVs includes exosomes and microvesicles. In the introduction, the authors only introduce the exosomes but not the microvesicles. Please add some information of microvesicles.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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25 Feb 2020

Reviewer \#1: Castro-Magdonel and colleagues carried out a survey on miRNAs from retinoblastoma children's plasma or extracellular vesicles and compared the miRNAs patterns with healthily age matched children, which provided us an informative resource of the landscape analysis of miRNAs in retinoblastoma children. However, there are some concerns should be addressed before consideration for publication.

The title of the manuscript is too long. Modifications required.

Response= We modified the manuscript title from a 30 word (233 characters) to 22 words (137 characters):

Plasma miRNome analysis from children with retinoblastoma reveals the size of the circulating miRNome, a tumor signature and novel candidates for normalizers.

Line 35: Circulating miRNAs are potential useful biomarkers in medicine.

Why they are only important in medicine? The authors should include all the related fields miRNAs involved.

R= we agree that miRNAs are important in many fields beyond medicine, to indicate this we included the following in the abstract's opening statement in the abstract:

"miRNAs regulate post-transcriptional gene expression in metazoans, and thus are involved in many fundamental cellular biological processes. Extracellular miRNAs are also found in most human biofluids including plasma. These circulating miRNAs constitute a long distance inter cellular communication system and are potentially useful biomarkers."

Line 39: To address these questions,

It seemed that the authors did not mention any questions or issues regarding miRNAs in previous couples' sentences. Clarify them.

R= we rearranged the text as follows:

We proposed to answer how many and which miRNAs are detectable in plasma or extracellular vesicles as these questions have not yet been answered. We set out to address this knowledge gap by analyzing the mirRNome in plasma and corresponding extracellular vesicles (EVs) from 12 children....

Line 67: In plasma have been found both, in soluble form associated to Argonaut proteins, and also inside extracellular vesicles or exosomes (6)(7). This sentence is hard and difficult to understand. Make it readable.

R= we agree and have modified the sentence as follows:

"In plasma, miRNAs associate with Argonaut proteins and can also be detected inside extracellular vesicles or exosomes (6)(7)."

Line 88 to Line 103:

The authors attempted to make their methodology more convincing, logic, and fit their study very well, but they failed. Recommends revision and rearrangements to make it concise and precise.

R= we understand the reviewer's suggestion and have modified and rearranged the paragraphs as follows:

"High throughput expression microarray technology can scan complete miRNnomes or transcriptomes in a single hybridization experiment. The original technology used a double channel platform and yielded relative measurements. However, more mature technology with one channel platforms include calibrators which yield absolute measurements. These calibrators allowed the development of robust methods for detection calls (19) which are basically ignored by most analysis. Broad maps of what is and is not detected can now be generated with the detection score using clustering tools thus facilitating data interpretation (20). This approach allows answering relevant questions such as 'how many' and 'which' miRNAs can be detected in plasma or EVs? Similarly, one can now posit: 'Are detectable miRNAs shared by all samples, phenotypes or experimental conditions?'

Materials and methods

The controls and the Rb patients' age and sex are not matched well. Also, the body weight or BMI, and race should be included if it is not unavailable to the authors.

R= as noted in table 1, age and gender did not differ significantly between the 12 cases and the 12 healthy controls. Weight at time of blood draw was not available for all cases and controls. All children were of Hispanic ethnicity. We do not collect information on 'race' in the underlying study as we do not feel that it would be meaningful or easily interpretable in the context of our population which is expected to have high and variable racial admixture.

Further, in microarray experiments, variations of expression measurements can be attributed to many different sources that influence the stability and reproducibility of microarray platforms. How the authors handle this issue?

R= One of the motivations to do this study is the remarkable stability of miRNAs in plasma. The samples have been collected under standard procedures and kept at 4°C until plasma separation (within 6 hours of sample collection) and then kept frozen at -70 °C until RNA isolation. Our analytic approach focused first on generating the detection score that simplifies handling microarray data, and later on examination of expression measurements. In our pilot work, we performed technical replicas, and since both expression and detection data were highly correlated, we opted to prioritize more biological replicas in our design instead of additional technical replicas. Expression measurements in microarray platforms are very sensitive and detect large amounts of 'noise'. We believe that this sensitivity masks underlying data patterns which are unmasked by using the detection score.

Is normalization applied when process the data?

R= Yes, we indicated this in the Data Analysis section Lines 147-148.

Results and discussions

There are several studies reported about 1000 to 2000 miRNAs in Rb patients' plasma (<https://www.ncbi.nlm.nih.gov/> pmc/articles/PMC5493862/). Why the authors only detected about 600 miRNAs in plasma?

R=to our knowledge this is the first work reporting the plasma miRNnome from children with retinoblastoma. The article mentioned by the reviewer is our own previous report of the primary tumors which correspond to the samples mentioned in this manuscript. We have cited this article in our references as reference '(20)'. We used the same platform as described in that publication: Affymetrix chips miRNA 4 with 2578 miRNAs.

We do not know why do we are able to detect approximately 600 miRNAs in plasma. We can only speculate the reasons. Plasma can be considered a 'liquid' tissue, and as such only a subset of genetic elements from the total miRNnome are "expressed" or detected. It may follow the same tenet as that of tissue specificity, which is result from the expression of only a subset of the genes in the genome.

We realize that some information about the number of miRNAs per cluster shown in the detection map generated from the primary tumors is missing in Table 2. We have now added the corresponding data from the primary tumors.

Rb tissues 995 1441 142

How the authors validate the miRNA expression profile? Any qRT-PCR validation applied?

R= we used stem-loops and exiqon miRNA probes for 6 miRNAs with high expression levels from the 19 miRNA signature for RB cases. We obtained mixed results and only 3 miRNAs showed high detection levels with both experimental approaches. We think that qRT-PCR is not optimal for miRNA detection and believe that more reliable methods need to be developed.

The figures' resolution is always low, which are difficult to read.

R=we apologize for the difficulty in reading our images. With this revised submission, we submit better images with higher resolution.

Reviewer \#2: In this paper, the authors try to answer the questions what the differences are between the healthy person and Rb (diseased) person in terms of their miRNAs in plasma and extracellular vesicles using 12 patients and 12 controls. The size of miRNAs in plasma are 537 and in EV is 626. And they found that 19 miRNAs in plasma are significant between healthy and diseased person. And they also found 9 miRNAs that can be detected in all the samples, suggesting that these 9 miRNAs can be used as internal control. They also found that the gender is also a factor that affects the miRNAs between healthy and diseased person.

First, I think the English in this paper needs to be improved.

R= we apologize for the grammatical errors in our initial submission. We have carefully edited this revised submission and hope that it will be easier to read.

Second, I think using 12 patients and 12 control as samples are too few to get conclusion.

R= we recognize the sample size is small, however we believe our findings represent an important contribution that can advance the scientific field because we show a different analytic approach that opens up new possibilities for interpretation and permits extracting information that may potentially be useful in the field of using miRNAs as circulating biomarkers. We therefore consider our conclusions are informative and valid.

Third, the difference between the plasmid and EV in terms of its chemical components should be discussed in the paper.

R=the reviewer may refer to plasma instead of ´plasmid', we have now included the following text in the discussion:

"Our finding that miRNA contents in total plasma and EVs are distinct, may be particularly informative. One possible explanation may be that the purification of EVs may amplify signals from miRNAs that may not be detectable in miRNAs extracted from whole plasma. Importantly, the 19 miRNA signature that is able to discriminate Rb cases from healthy controls is found only in RNA from total plasma and not in EVs, this is relevant because the method to obtain RNA from plasma is simpler and less expensive than the method to obtain RNA from of EVs."

Other than that, I have some comments as below:

1\. Methods/Patients and samples: What are including criteria and what are excluding criteria?

R= we have now included the following text in the Methods, patients and samples section:

"Inclusion criteria: children newly diagnosed with retinoblastoma at an age of less than or equal to 6 years, without a known genetic syndrome or prior diagnosis of cancer, who were diagnosed or were receiving treatment at the two participating treatment centers, and did not have a preexisting/ known family history of retinoblastoma. One child later found to have familial retinoblastoma was included in the study.

Exclusion criteria: age greater than 6 years of age at time of diagnosis, known diagnosis of a genetic syndrome or prior diagnosis of cancer."

2\. How are the healthy control being selected?

R= Control selection used 'friend' controls as a proxy for population controls. Controls were children of women who were friends (but not a biological relative) of the mother of an eligible case child. Exclusion criteria for controls included being diagnosed with a known genetic syndrome, or having a family history of retinoblastoma, or a personal history of any type of cancer. Controls were within 2 years of age of the case child. We have included an abbreviated description of the source of the population at the beginning of the Materials and Methods section as we acknowledge that this should be included.

3\. How many times the experiments for Fig 1, 2, and 3 are done? If they are only done once, how do the authors make sure the results are reliable?

R= in our pilot work, we performed a technical replica for 1 tumor (2 microchips) and for 1 plasma (2 microchips), and since expression and detection data had a very high correlation, we decided to include in the design more biological replicas to obtain more information on reproducibility and biological variability. We performed tumor experiments 12 times, plasma experiments 24 times and EVs experiments 24 times, we believe these make our results reliable.

4\. In figure 3 and 4, how top is the top ranked miRNAs?

R=Figure 3 is a detection map generated with hierarchical clustering using the detection score for miRNAs isolated from EVs, there are no top ranked miRNAs in Fig 3.

Figure 4 shows heatmaps and volcano plots generated with the results of differential analysis using expression data. We used the expression 'top ranked' to identify in the output results table, all significant over expressed miRNAs in the Rb cases. The results of Differential Analysis are lists of miRNAs with log2 transformed values, this transformation is performed to obtain symmetrical data, positive numbers for Rb cases, and negative numbers for healthy controls. We ordered this transformed values from large to small to identify at the top of positive values, those miRNAs over expressed in Rb cases.

To avoid confusion, we added the following:

In the differential analysis we found 158 differentially expressed miRNAs in plasma and 142 differentially expressed miRNAs in EVs. However, adjusted p values indicate that differences were not significant for any of them.

We also change the expression top ranked to 'The most differentially expressed' miRNAs in the table 3 and 4 titles.

We also added before description of figure 4 the following:

The corresponding heatmap does not show color differences among cases and controls except for the 158 and 142 differentially expressed miRNAs which are shown in Fig 4. Even though differential analysis identified miRNAs with p-values \<0.05, the adjusted p-values did not show any statistically significant differences between cases and controls for any miRNA.

Are the top miRNAs showed in Table 3 and Table 4 same as those detected by mirnomic analysis?

R= Yes, the top miRNAs showed in Table 3 and Table 4 are the same as those indicated in the volcano plots in figure 4 b and d. We are submitting a better quality figure with larger fonts to enhance the readability of the miRNA identifiers.

5\. In Figure 5 and table 5, the authors summarized the number of detected miRNAs per sample, per group (cases or controls) and per class. How does these numbers compare to other mirnome studies?

R=to our knowledge this is the first work reporting the size of plasma miRNome using the terms 'detected' miRNAs. We added in table 2 miRNome data from the corresponding primary tumors:

Rb tissues 995 1441 142

6\. Figure 7 indicated that gender may be a factor that cause the miRNA to be different. So Could the authors analyze the difference of miRNA in plasma and EV between diseased person and health person with gender differences? So there will be four groups: 1) health female, 2) health male, 3) diseased female, and 4) diseased male.

R= We think that in order to interpret this findings, more balanced groups are needed with equal number of males and females in each group. Since our sex related findings were unexpected we didn't consider this balance in the study design. Nonetheless we now submit the requested analysis and groups obtained with hierarchical clustering of detection scores and a summary of this analysis in the following table:

Groups Condition \# miRNAs

shared

Group 1 Healthy females in Plasma 21

Healthy females in EVs 33

Group 2 Healthy males in Plasma 22

Healthy males in EVs 62

Group 3 Rb females in Plasma 63

Rb females in EVs 73

Group 4 Rb males in Plasma 36

Rb males in EVs 44

7\. The authors found that 19 miRNAs shared exclusively by all Rb cases. Are these 19 miRNAs have any similarities? Which pathways did these 19 miRNAs targeted? How about this result compared with other similar results? Is there any difference? If yes, why?

R= from the 19 miRNAs in plasma that were shared by all Rb cases, 14 are also part of the 142 miRNA core shared by all the primary tumors described in (20). For the 19 miRNAs found, using mirPath v.3 we found 51 KEGG pathways with a wide variety of biologic functions which probably reflect the physiologic processes in which the circulating miRNAs are involved. There are no similar results in the literature.

8\. Why "miR-16-5p signals are detectable in 17 / 21 samples mainly in EVs" but not all the samples in EVs? And why "miR-21 is detected only in a few samples" but not all the samples? Since miR-16 and miR-21 are all normalizers, they should be seen in all the samples?

R= miR-16 and miR-21 are the most common miRNA used as normalizers for plasma with qRT-PCR. Ideally a normalizer should be detectable in all the samples. Our data show that these two common normalizers are not detected in all samples. However, we found 9 miRNAs that were detectable in all the samples, making these nine better candidates to be used as normalizers. We do not know why miR-16 and miR-21 are not detectable in all of our samples.

9\. Line 319: "13 miRNAs as a signature are exclusively detected in EVs from Rb cases." Please delete exclusively because it is not exclusive as 12miRNAs are also seen in healthy controls.

R= we agree that the word produces confusion, our apology for this we eliminated it.

10\. Why "more robust circulating Rb case signature is in the plasma compartment not in EVs"? Could the authors give an explanation?

R= this work essentially describes what can be detected in plasma and EVs using the detection score. At this moment we can only speculate about why the plasma signature clearly better discriminates Rb cases from healthy controls compared with the EVs signature. One possibility is that detectable miRNAs in plasma might reflect both the circulating tumor message as well as a systemic response to cancer.

11\. Line 302-303: "the differences are found not too strong" is too subjective. Please revise this sentence, e.g., adding a reference.

R= We change the sentence as follows:

"The corresponding heatmap does not show color differences among cases and controls except for the 158 and 142 differentially expressed miRNAs which are shown in Fig 4. Even though differential analysis identified miRNAs with p-values \<0.05, the adjusted p-values did not show any statistically significant differences between Rb cases and controls for any miRNA."

12\. Table 1: Did the authors do the statistical analysis on the patient gender between the health and diseased group?

R= we compared the sex distribution between cases and controls and found no statistical difference. We have now added this in the footnote to the table.

13\. EVs includes exosomes and microvesicles. In the introduction, the authors only introduce the exosomes but not the microvesicles. Please add some information of microvesicles.

R= we arranged information in the introduction stating that:

"In plasma, exosomes are part of extracellular vesicles (EVs) that include particles of diverse sizes and origins which are not fully characterized. There is not a standard definition of what exosomes are. In practical terms these are mixed populations of membranous nanosized particles about 50-130 nm in diameter (8)(9)(10).
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?
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Castro-Magdonel et al., improved the manuscript following the reviewers\' suggestion and respond to all comments one by one. There are two common issues in this manuscript. One is all tables should be three-line table.

R= Following the Table guidelines we formatted the tables as requested and divided table 6 and thus we present now a table 7 and change the text accordingly.

The second issue is all references should be formatted following Submission Guidelines, <https://journals.plos.org/plosone/s/submission-guidelines#loc-references>. All references should be double manually checked after formatting using common reference management software such as Endnote and disconnecting from the reference management software. For example, Ref. 3, Bartel DP. MicroRNAs. Cell \[Internet\]. 2004 Jan 23 \[cited 2018 Apr 30\];116(2):281--97. Available from:<http://linkinghub.elsevier.com/retrieve/pii/S0092867404000455>, could be formatted as: Bartel DP. MicroRNAs. Cell. 2004 Jan 23;116(2):281--97. In addition, subtitle Bibliography should be replaced by References.

R= We double manually checked all references following Plos guidelines for references.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have all my concerns addressed. There is no more questions on this manuscript. I suggest to accepting it for publication on PLOS One.

Reviewer \#2: Thank you for taking care of review's question. I have some comments:

1\. Review 1/Question 1: the title still needs to be changed. Please specify how does the size of the circulating miRNome change and how does tumor signature change in the title.

Response= We recognize the requested modification of the title may better reflect the main contribution of this work to the field, we changed the title accordingly:

Circulating miRNome detection analysis reveals 537 miRNAS in plasma, 625 in extracellular vesicles and a discriminant plasma signature of 19 miRNAs in children with retinoblastoma from which 14 are also detected in corresponding primary tumors

2\. Review 1/M&M: Please include "All children were of Hispanic ethnicity." in the text.

R= we included all children were of Hispanic ethnicity in the "Patients and samples" section. We do not understand what M&M means.

3\. Review 2/Question 1: please add explanation why year 6 is a cut-off line.

R= this is because the majority of newly diagnosed Rb cases fall under 6 year of age, we added the following in "Patients and samples" section: \...children newly diagnosed with retinoblastoma at an age of less than or equal to 6 years since most affected patients are in this age group.

4\. Review 2/Question 10: please add explanation in the text.

R= We included the following in the "Discusion" section: At this moment we can only speculate about why the plasma signature clearly better discriminates Rb cases from healthy controls compared with the EVs signature. One possibility is that detectable miRNAs in plasma might reflect both the circulating tumor message as well as a systemic response to cancer,\...

5\. Review 3/Question 7 and 8: is the inconsistency with other literature and within the experiment an indication of something went not well in the experiment?

R= Question 7 is related to the 19 miRNAs shared by all Rb cases. We previously explained that 51 KEGG pathways are affected by the 19 miRNA signature covering a wide biological group of functions. The fact that there are no other reports in the literature similar to our findings is not an inconsistency; it rather reflects the novelty of our analytical approach and findings. It is not clear for us what inconsistency within the experiment the reviewer refers to.

For example, reproducibility?

R= One of the motivations to do this study is the remarkable stability reported for miRNAs in plasma. In order to assure reproducibility the samples have been collected under standard procedures, kept at 4°C until plasma separation (within 6 hours of sample collection), and then kept frozen at -70 °C until RNA isolation. Our analytic approach focused first on generating the detection score that simplifies microarray data, and later on examination of expression measurements. In our pilot work, we performed technical replicas, and since both expression and detection data were highly correlated, we opted to prioritize more biological replicas in our design instead of additional technical replicas in order to find reproducible patterns shared by Rb cases. Expression measurements in microarray platforms are very sensitive and detect large amounts of 'noise'. We believe that this sensitivity masks underlying data patterns, which are unmasked by using the detection score.

R= we included the following in the "Discussion" section:

One of the motivations to do this study is the remarkable stability reported for miRNAs in plasma. In order to assure reproducibility the samples have been collected and processed under standard procedures. Our analytic approach focused first on generating the detection score that simplifies microarray data, and later on examination of expression measurements. In our pilot work, we performed technical replicas, and since both expression and detection data were highly correlated, we opted to prioritize and include more biological replicas in our design instead of additional technical replicas, to increase the possibilities of finding patterns shared by Rb cases. Expression measurements in microarray platforms are very sensitive and detect large amounts of 'noise', we believe that this sensitivity masks underlying data patterns, which are unmasked by using the detection score.

Question 8 is related to miR-16-5p and miR-21, common normalizers used for qRT-PCR in plasma. We rather think our results are consistent with the literature adding precision to what is known, since we show that the compartment on which miR-16-5p is detected in most samples are EVs. We expand current knowledge by showing average detection levels as well as variability measurements (variance) across the samples under study. The contrast of this features particularly the expression levels between these common normalizers and the three most highly expressed newly proposed normalizers (miR-5787, 638 and 6732-5p) show that the later have higher detection levels and justify to continue the experimental exploration for using them as normalizers.

R= we included the following in the "Discussion" section:

Our results add precision and expand information on miR-16-5p and miR-21 common normalizers for qRT-PCR in plasma, since we show that the blood compartment on which miR-16-5p is detected in most samples are EVs. We also show and contrast average detection levels as well as variability measurements (variance) across the samples under study. The expression levels between these common normalizers and the three most highly expressed newly proposed normalizers (miR-5787, 638 and 6732-5p) show that the later have higher detection levels and justify to continue the experimental exploration for using them as normalizers.
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For any other questions or concerns, please email <plosone@plos.org>.
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